Champions Oncology, Inc.

CSBR Healthcare Biotechnology

Champions Oncology, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $59.4 million, up 4.36% from fiscal 2025.

Revenue
+8.84%
EPS
0.00%
Free cash flow
−198.7%

Quarter to July 2026, against a year earlier

4.80 0.04 +0.84%
Market cap
$66.3M
P/E
0.0×
Fwd P/E
−41.6×
Dividend yield
—
F-score
3/9
Altman Z
−0.02
Beneish M
−1.80
Dividend safety
n/a
Older periods Oct '25 Jan '26 Apr '26 Jul '26
Piotroski F-Score

+8 more TTM periods

8 3 3 3
ROE
100.24% (46.96%) (29.97%) (28.38%)
ROA
8.89% (7.83%) (3.96%) (3.56%)
ROIC
0.00% 0.00% 0.00% (626.23%)
Return on Tangible Assets
78.36% (71.96%) (41.62%) (26.09%)
Average Days of Receivables
72.09 76.01 80.94 81.84
Free Cash Flow per Share
0.41 0.28 (0.36) (0.44)
Free Cash Flow
5.64 3.84 (5.01) (6.11)
Other line items

Show all line items

Columns are period end dates